Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 8:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Hypertension
Interventions: Azilsartan Medoxomil and amlodipine, Amlodipine; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 50
States / cities: Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 47 more

Conditions: Allergic Conjunctivitis
Interventions: REGN5713, REGN5715, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Glabellar Frown Lines
Interventions: AbobotulinumtoxinA, Placebo; Biological · Other
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 11
States / cities: Redondo Beach, California • San Diego, California • Westport, Connecticut + 8 more

Conditions: Degenerative Disc Disease
Interventions: NuQu, Placebo; Biological · Other
Lead sponsor: ISTO Technologies, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Santa Monica, California + 7 more

Conditions: Hypertension
Interventions: MobiusHD™; Device
Lead sponsor: Vascular Dynamics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 7
States / cities: Birmingham, Alabama • Atlanta, Georgia • Des Moines, Iowa + 4 more

Conditions: Pain, Intractable, Pain Cancer, Pain
Interventions: Resiniferatoxin, Placebo; Drug
Lead sponsor: Sorrento Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: La Jolla, California • Gainesville, Florida • Portland, Oregon + 1 more

Conditions: Hidradenitis Suppurativa
Interventions: RIST4721, Placebo; Drug
Lead sponsor: Aristea Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 7 more

Conditions: Diabetic Foot Ulcers
Interventions: Gentamicin Topical Gel, Ciprofloxacin, Doxycycline; Drug
Lead sponsor: Royer Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Miami, Florida • Miami Lakes, Florida + 4 more

Conditions: Atopic Dermatitis
Interventions: 1.1% w/w AMTX-100 CF-part1, Placebo, 1.1% w/w AMTX-100 CF3-part2; Drug
Lead sponsor: Amytrx Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 11
States / cities: Cerritos, California • Encino, California • Long Beach, California + 8 more

Conditions: Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions: TBAJ-876 suspension, Placebo suspension, TBAJ-876 100 mg tablet, TBAJ-876 25 mg tablet; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Participants
Interventions: Eplontersen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cypress, California

Conditions: Postsurgical Pain
Interventions: CA-008, Placebo; Drug
Lead sponsor: Concentric Analgesics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Schizophrenia
Interventions: Inhaled Placebo, Inhaled Loxapine 5 mg, Inhaled Loxapine 10 mg; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Upland, California

Conditions: Obesity
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 41
States / cities: Tucson, Arizona • Loma Linda, California • Los Angeles, California + 33 more

Conditions: Safety Issues
Interventions: EQU-001, Placebo; Drug
Lead sponsor: Equilibre Biopharmaceuticals B.V.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Urolithiasis
Interventions: Ultrasound guidance; Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Erythematotelangiectatic Rosacea
Interventions: CD07805/47, CD07805/47 placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 5
States / cities: Hot Springs, Arkansas • Fort Washington, Pennsylvania • Austin, Texas + 2 more

Conditions: Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
Interventions: Imvotamab, Placebo; Drug
Lead sponsor: IGM Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Flagstaff, Arizona • Glendale, Arizona • San Diego, California + 7 more

Conditions: Lysosomal Acid Lipase Deficiency
Interventions: Sebelipase Alfa, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 11
States / cities: Tucson, Arizona • Palo Alto, California • San Francisco, California + 8 more

Conditions: Healthy
Interventions: Placebo, JNJ-64281802 High dose, JNJ-64281802 Medium dose, JNJ-64281802 Low dose, JNJ-64281802 Dosing Regimen X, JNJ-64281802 Dosing Regimen Y, JNJ-64281802 Dosing Regimen Z; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver, NAFLD
Interventions: Rencofilstat, Placebo; Drug
Lead sponsor: Hepion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 39
States / cities: Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 33 more

Conditions: Intraocular Pressure
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 321 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Dermatitis, Atopic
Interventions: PF-04965842 100 mg, PF-04965842 200 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 28
States / cities: Anaheim, California • Los Alamitos, California • Rolling Hills Estates, California + 20 more

Conditions: Ornithine Transcarbamylase (OTC) Deficiency
Interventions: scAAV8OTC, Reactive Corticosteroid Taper Regimen, Prophylactic Corticosteroid Taper Regimen; Genetic · Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more

Search by objective public record fields.

Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy

Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines

A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo

Controlling and Lowering Blood Pressure With The MOBIUSHD™

Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer

A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)

Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese Participants

Study of CA-008 (Vocacapsaicin) in Total Knee Arthroplasty

Staccato Loxapine in Agitation (Proof of Concept)

Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

Safety, Tolerability, and Pharmacokinetics of EQU-001 in Healthy Volunteers

Management of Ureteral Calculi Using Ultrasound Guidance: A Radiation Free Approach

Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea

A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis

Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency

A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants

A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis

A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset Ornithine Transcarbamylase (OTC) Deficiency